Polymorphisms of the FAS and FASL genes and risk of breast cancer

Oncology Letters

Volumn 3, Issue 3, 2012, Pages 625-628

  Wang, Wenmin ^a   Zheng, Zhongqiu ^a   Yu, Wenjie ^a   Lin, Hui ^a   Cui, Binbin ^a   Cao, Feilin ^a  

^a TAIZHOU HOSPITAL OF ZHEJIANG PROVINCE   (China)

Author keywords

Breast cancer; FAS; FASL; Risk

Indexed keywords

FAS ANTIGEN; FAS LIGAND;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RISK; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TUMOR GENE; WILD TYPE;

EID: 84862909439     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.541     Document Type: Article

References (28)

1. Fan XQ and Guo YJ: Apoptosis in oncology. Cell Res 11: 1-7, 2001.
2. Evan GI and Vousden KH: Proliferation, cell cycle and apoptosis in cancer. Nature 411: 342-348, 2001.
3. Andera L: Signaling activated by the death receptors of the TNFR family. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 153: 173-180, 2009.
4. Kim R, Emi M, Tanabe K, Uchida Y and Toge T: The role of Fas ligand and transforming growth factor β in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy. Cancer 100: 2281-2291, 2004.
5. Reichmann E: The biological role of the Fas/FasL system during tumor formation and progression. Semin Cancer Biol 12: 309-315, 2002.
6. Randhawa SR, Chahine BG, Lowery-Nordberg M, Cotelingam JD and Casillas AM: Underexpression and overexpression of Fas and Fas ligand: a double-edged sword. Ann Allergy Asthma Immunol 104: 286-292, 2010.
7. Whiteside TL: The role of death receptor ligands in shaping tumor microenvironment. Immunol Invest 36: 25-46, 2007.
8. Fulda S and Pervaiz S: Apoptosis signaling in cancer stem cells. Int J Biochem Cell Biol 42: 31-38, 2010.
9. Houston A and O'Connell J: The Fas signalling pathway and its role in the pathogenesis of cancer. Curr Opin Pharmacol 4: 321-326, 2004.
10. Wajant H: The Fas signaling pathway: more than a paradigm. Science 296: 1635-1636, 2002.
11. Huang QR, Morris D and Manolios N: Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol 34: 577-582, 1997.
12. Wu J, Metz C, Xu X, Abe R, Gibson AW, Edberg JC, Cooke J, Xie F, Cooper GS and Kimberly RP: A novel polymorphic CAAT/enhancer-binding protein β element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. JImmunol 170: 132-138, 2003.
13. Zhang Z, Qiu L, Wang M, Tong N, Li J and Zhang Z: The FAS ligand promoter polymorphism, rs763110 (-844C>T), contributes to cancer susceptibility: evidence from 19 case-control studies. Eur J Hum Genet 17: 1294-1303, 2009.
14. Zhang Z, Xue H, Gong W, Wang M, Yuan L, Han S and Zhang Z: FAS promoter polymorphisms and cancer risk: a meta-analysis based on 34 case-control studies. Carcinogenesis 30: 487-493, 2009.
15. Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236, 2011.
16. Keane MM, Ettenberg SA, Lowrey GA, Russell EK and LipkowitzS: Fas expression and function in normal and malignant breast cell lines. Cancer Res 56: 4791-4798, 1996.
17. Herrnring C, Reimer T, Jeschke U, Makovitzky J, Krüger K, Gerber B, Kabelitz D and Friese K: Expression of the apoptosis-inducing ligands FasL and TRAIL in malignant and benign human breast tumors. Histochem Cell Biol 113: 189-194, 2000.
18. Müllauer L, Mosberger I, Grusch M, Rudas M and Chott A: Fas ligand is expressed in normal breast epithelial cells and is frequently up-regulated in breast cancer. J Pathol 190: 20-30, 2000.
19. Sun T, Miao X, Zhang X, Tan W, Xiong P and Lin D: Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst 96: 1030-1036, 2004.
20. Zhang X, Miao X, Sun T, Tan W, Qu S, Xiong P, Zhou Y and Lin D: Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer. J Med Genet42: 479-484, 2005.
21. Lai HC, Sytwu HK, Sun CA, Yu MH, Yu CP, Liu HS, Chang CC and Chu TY: Single nucleotide polymorphism at Fas promoter is associated with cervical carcinogenesis. Int J Cancer 103: 221-225, 2003.
22. Liu Y, Wen QJ, Yin Y, Lu XT, Pu SH, Tian HP, Lou YF, TangYN, Jiang X, Lu GS and Zhang J: FASLG polymorphism is associated with cancer risk. Eur J Cancer 45: 2574-2578, 2009.
23. Wang LH, Ting SC, Chen CH, Tsai CC, Lung O, Liu TC, LeeCW, Wang YY, Tsai CL and Lin YC: Polymorphisms in the apoptosis-associated genes FAS and FASL and risk of oral cancer and malignant potential of oral premalignant lesions in a Taiwanese population. J Oral Pathol Med 39: 155-161, 2010.
24. Kang S, Dong SM, Seo SS, Kim JW and Park SY: FAS -1377 G/A polymorphism and the risk of lymph node metastasis in cervical cancer. Cancer Genet Cytogenet 180: 1-5, 2008.
25. Qiu LX, Shi J, Yuan H, Jiang X, Xue K, Pan HF, Li J and ZhengMH: FAS -1,377 G/A polymorphism is associated with cancer susceptibility: evidence from 10,564 cases and 12,075 controls. Hum Genet 125: 431-435, 2009.
26. Shimonishi T, Isse K, Shibata F, Aburatani I, Tsuneyama K, SabitH, Harada K, Miyazaki K and Nakanuma Y: Up-regulation of fas ligand at early stages and down-regulation of Fas at progressed stages of intrahepatic cholangiocarcinoma reflect evasion from immune surveillance. Hepatology 32: 761-769, 2000.
27. Yang M, Sun T, Wang L, Yu D, Zhang X, Miao X, Liu J, ZhaoD, Li H, Tan W and Lin D: Functional variants in cell death pathway genes and risk of pancreatic cancer. Clin Cancer Res 14: 3230-3236, 2008.
28. Zhu J, Qin C, Wang M, Yan F, Ju X, Meng X, Ding Q, Li P, Yang J, Cao Q, Zhang Z and Yin C: Functional polymorphisms in cell death pathway genes and risk of renal cell carcinoma. Mol Carcinog 49: 810-817, 2010.